Haemonetics
HAE
306 hedge funds and large institutions have $4.49B invested in Haemonetics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 107 increasing their positions, 112 reducing their positions, and 53 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5% more call options, than puts
Call options by funds: $47.1M | Put options by funds: $45M
0.4% less ownership
Funds ownership: 109.55% → 109.15% (-0.4%)
3% less capital invested
Capital invested by funds: $4.62B → $4.49B (-$131M)
4% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 112
3% less funds holding
Funds holding: 317 → 306 (-11)
17% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$97.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.1M |
| 3 |
SCM
SG Capital Management
Chicago,
Illinois
|
+$37.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.4M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
+$27.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$200M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$60M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$20.1M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$20.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.1M |
HAE Hedge Fund Activity: Q3 2024 in Review
306 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2024, worth a combined $4.49B — down 2.8% from $4.62B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of HAE and 44 opened new positions — a net loss of 9 holders — while 112 trimmed existing stakes and 107 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $97.6M. The largest seller was Capital Research Global Investors, cutting an estimated $200M.
- 306 institutional investors held Haemonetics (HAE) as of Q3 2024, down from 317 in Q2 2024.
- Funds reported $4.49B of Haemonetics stock for Q3 2024, down 2.8% quarter-over-quarter.
- 44 funds opened new Haemonetics positions in Q3 2024 and 53 closed out, a net change of -9 holders.
- The largest Haemonetics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $97.6M added.
- The largest Haemonetics seller in Q3 2024 was Capital Research Global Investors, an estimated $200M sold.
Based on aggregated 13F filings for Q3 2024.